Development of monoclonal gammopathy under biotherapy in psoriasis: a French multicenter retrospective study

Background Biotherapies or targeted therapies are fairly new treatments indicated for moderate to severe psoriasis. The side effects appear to be mainly infectious or cancerous. The role of biotherapies in the development of a pre-cancerous condition, monoclonal gammopathy of undetermined significan...

Full description

Saved in:
Bibliographic Details
Published in:EJD. European journal of dermatology 2016, Vol.26 (1), p.75-81
Main Authors: Liegeon, Anne-Laure, Mahe, Emmanuel, Begon, Edouard, Poreaux, Claire, Barbaud, Annick, Esteve, Eric, Quiles-Tsimaratos, Nathalie, Avenel-Audran, Martine, Schoeffler, Amélie, Mery-Bossard, Laure, Pauwels, Christine, Girard, Céline, Maillard, Hervé, Barthelme, Dominique, Bernier, Claire, Chaby, Guillaume, Reguiai, Ziad, Nguyen-Thi, Phi Linh, Maccari, François, Schmutz, Jean-Luc
Format: Article
Language:English
Subjects:
Adult
Aged
Biological Factors - adverse effects
Dermatology
Female
Human health and pathology
Humans
Investigative Report
Life Sciences
Male
Medicine
Medicine & Public Health
Middle Aged
Paraproteinemias - etiology
Psoriasis - immunology
Psoriasis - therapy
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Biotherapies or targeted therapies are fairly new treatments indicated for moderate to severe psoriasis. The side effects appear to be mainly infectious or cancerous. The role of biotherapies in the development of a pre-cancerous condition, monoclonal gammopathy of undetermined significance (MGUS), has recently been debated in the literature. Objectives To evaluate the incidence of MGUS in psoriasis patients treated with biotherapy. Materials and Methods This study was a French multicenter retrospective study carried out through the French multicenter study group RESOPSO. Data on the results of serum protein electrophoreses performed before and within at least six months after the start of the biotherapy were collected. Demographic data, medical history, and psoriasis treatment history were specified. Results Four hundred and forty three patients were eligible for inclusion. Of these, three presented with monoclonal gammopathy for which the assessment was in favor of MGUS. The average treatment period was 19.7 months. Six patients presented withMGUSprior to the treatment. These patients’ immunoglobulin levels remained stable, with an average remission of 24 months. Only psoriatic rheumatism appeared to be statistically linked to MGUS. Conclusion The incidence and frequency ofMGUSin psoriasis patients treated with biotherapy do not appear to increase relative to the general population.
ISSN:1167-1122
1952-4013
DOI:10.1684/ejd.2015.2700